LON:CEL

Celadon Pharmaceuticals (CEL) Share Price, News & Analysis

Celadon Pharmaceuticals logo
GBX 13.40 0.00 (0.00%)
As of 08/6/2025

About Celadon Pharmaceuticals Stock (LON:CEL)

Key Stats

Today's Range
13.40
▼
13.40
50-Day Range
13.40
▼
13.40
52-Week Range
2.21
▼
83
Volume
N/A
Average Volume
226,267 shs
Market Capitalization
£8.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation, proprietary GMP extraction and an analytical and R&D laboratory. Celadon's Home Office licence allows for the commercial supply of its pharmaceutical-grade cannabis product. The Group owns an approved clinical trial using cannabis-based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics, which is developing a licensed cannabinoid medicine to treat children with Autism Spectrum Disorder. For further information please visit our website www.celadonpharma.com

Receive CEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celadon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CEL Stock News Headlines

Top Trader Reveals Stunning Black Friday Deal
Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.tc pixel
See More Headlines

CEL Stock Analysis - Frequently Asked Questions

Celadon Pharmaceuticals' stock was trading at GBX 13.40 at the start of the year. Since then, CEL shares have increased by 0.0% and is now trading at GBX 13.40.

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
LON:CEL
CIK
N/A
Fax
N/A
Employees
2,780
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
GBX (7.98)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-£4.97 million
Net Margins
-9,520.00%
Pretax Margin
N/A
Return on Equity
-131.82%
Return on Assets
-34.40%

Debt

Debt-to-Equity Ratio
149.37
Current Ratio
2.62
Quick Ratio
6.97

Sales & Book Value

Annual Sales
£123.38 thousand
Price / Sales
66.61
Cash Flow
GBX 4.39 per share
Price / Cash Flow
3.05
Book Value
GBX 3.80 per share
Price / Book
3.53

Miscellaneous

Outstanding Shares
61,329,971
Free Float
N/A
Market Cap
£8.22 million
Optionable
Not Optionable
Beta
-0.26
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (LON:CEL) was last updated on 8/6/2025 by MarketBeat.com Staff.
From Our Partners